Treatment of Ewing's Sarcoma with Pulmonary Metastases Not Progressing on Induction Chemotherapy

Clinical Scenario

This protocol addresses patients with Ewing's sarcoma who present with pulmonary metastases and whose disease is not progressing on induction chemotherapy. Demonstrating stable or responding disease during induction is the pivotal criterion that determines eligibility for the local pulmonary component of treatment.

Pulmonary Metastases

For patients with pulmonary metastases, whole lung irradiation following systemic chemotherapy is indicated when the disease is not progressing on induction. Tumour volume change on MRI reliably reflects chemotherapy response and informs this assessment.

Treatment Approach Partial preview

The strategy centres on compressed-interval combination chemotherapy paired with local control of the primary tumour, with whole lung irradiation incorporated for the pulmonary disease in responding patients — the complete regimen, sequence, and modality selection are detailed in the full protocol.

Clinical Goals

Key treatment targets include a histological necrosis rate greater than 90% in the resected specimen and tumour volume reduction on MRI as a measure of chemotherapy response.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1038/s41416-024-02868-4

For patients with pulmonary metastases, whole lung irradiation (WLI) following VDC/IE chemotherapy is indicated if the disease is not progressing on induction chemotherapy.

Greater treatment intensity is linked to better outcomes: a two-weekly interval-compressed VCD/IE induction was demonstrated to be more effective than the same regimen given three-weekly and VDC/IE induction followed by IE/VC consolidation has better outcomes than VIDE induction and VAI or VAC consolidation and is now the preferred first-line treatment for all patients who are medically fit to receive it.

Tumour volume change can be seen on MRI, and reliably reflects chemotherapy response particularly if late.

if there is a poor histological response (≤90% necrosis) to pre-operative chemotherapy, even if the resection margins are negative

View source ↗